Phase 2 Results of Tildrakizumab Show Significant Joint, Skin Improvements in Adults With Active Psoriatic Arthritis
Tildrakizumab is an IL-23 inhibitor indicated for adults with moderate-to-severe plaque psoriasis and is under investigation for PsA.
Phase 2 results from the first trial of tildrakizumab-asmn (Ilumya, Sun Pharma) in adults with active psoriatic arthritis (PsA) found significant improvements in several signs and symptoms, according to data presented at the European E-Congress of Rheumatology last week.1
Tildrakizumab is an IL-23 inhibitor indicated for adults with moderate-to-severe plaque psoriasis and is under investigation for PsA.1
PsA is a chronic, inflammatory disease affecting the joints and places where tendons and ligaments connect to bone.2 The disease leads to inflammation, which causes swelling, pain, and stiffness in the joints, as well as fatigue. PsA affects up to 42% of people with plaque psoriasis in the United States, and typically begins between ages 30 and 50, although it can start at any age.2
Of 500 patients screened for the study, 391 were randomized and received 1 or more doses of the drug. From baseline to week 24, 1 case of pyelonephritis and urinary tract infection and 1 case of chronic tonsillitis was reported. No deaths or major adverse cardiac events occurred.1
In adults with active PsA, the new phase 2 results met primary and secondary efficacy and safety endpoints with statistical significance at week 24. In patients who received tildrakizumab, signs and symptoms including tender and swollen joints, levels of skin clearance, and minimal disease activity response all improved through week 24 and were maintained through week 52. For patients who received 100 mg of the drug, results were seen as early as 8 weeks.1
REFERENCES
- Mease P, Chohan S, Fructuoso F, et al. Efficacy and Safety of Tildrakizumab, a High-Affinity Anti-Interleukin-23P19 Monoclonal Antibody, In Patients with Active Psoriatic Arthritis in a Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2B Study. Abstract, EULAR 2020; Presented June 5, 2020. http://scientific.sparx-ip.net/archiveeular/index.cfm?c=a&view=1&searchfor=tildrakizumab&item=2020OP0230. Accessed June 8, 2020.
- National Psoriasis Foundation. About Psoriatic Arthritis; updated January 15, 2020. https://www.psoriasis.org/about-psoriatic-arthritis#:~:text=Psoriatic%20arthritis%20is%20a%20chronic,between%20ages%2030%20and%2050. Accessed June 8, 2020.
